Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD 521873 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EMD 521873 | BIOLOGICAL | After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively. |
Inclusion Criteria: * Histologically or cytologically confirmed NSCLC stage IIIb with malignant pleural effusion or stage IV * Pulmonary primary tumor or at least one NSCLC metastasis in the lung measuring at least 1 cm in diameter and eligible for local radiation with 20 Gy * Disease control (part...
Top 20 of 76 competitors
EMD 521873 is an investigational monoclonal antibody being studied for the treatment of lung cancer, specifically non-small cell lung cancer (NSCLC). It is being evaluated in combination with radiotherapy in patients with this condition.
EMD 521873 is being developed by Merck KGaA, a pharmaceutical company traded under the ticker MKGAF. The drug is currently in clinical development for oncology indications, including lung cancer.
EMD 521873 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active trials.
EMD 521873 has been studied in one clinical trial, NCT00879866, titled 'EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)'. This Phase 1 trial enrolled 15 participants in the Netherlands and has been completed.
EMD 521873 is a monoclonal antibody, a type of targeted therapy designed to bind to specific proteins involved in cancer growth. Its exact molecular target has not been disclosed in available information.